



April 24, 2026

The Honorable Richard W. "Rick" Allen  
U.S. House of Representatives  
462 Cannon House Office Building  
Washington, DC 20515

Dear Representative Allen:

On behalf of the Association for Accessible Medicines (AAM) and its Biosimilars Council, I write to express our strong support for the *PBM Kickback Prohibition Act* (H.R. 7895). Your legislation takes an important step toward addressing misaligned incentives in the prescription drug supply chain by prohibiting pharmacy benefit managers from paying compensation to brokers, consultants, and other intermediaries in exchange for steering employer health plan business. As outlined in your bill, this targeted amendment to ERISA would help reduce conflicts of interest and improve transparency in how pharmacy benefit decisions are made for employer-sponsored plans.

AAM's member companies, which manufacture the majority of generic and biosimilar medicines dispensed in the United States, have consistently highlighted how current PBM business practices can distort competition and limit patient access to lower-cost medicines. When intermediaries are incentivized through financial arrangements that are not aligned with plan sponsors or patients, it can result in formulary and coverage decisions that favor higher-cost products over more affordable generic and biosimilar alternatives. By prohibiting these kickback arrangements, your legislation helps ensure that decisions are based on value and clinical appropriateness rather than financial incentives, ultimately supporting a more competitive and efficient pharmaceutical marketplace.

We commend your leadership in advancing practical, market-based solutions to lower prescription drug costs and improve accountability in the healthcare system. The *PBM Kickback Prohibition Act* represents a meaningful step toward restoring integrity in the pharmacy benefit ecosystem and strengthening access to affordable medicines for patients and employers alike. AAM stands ready to work with you and your colleagues to advance this legislation and to continue pursuing reforms that promote competition, transparency, and patient access.

Sincerely,

A handwritten signature in black ink, appearing to read "John Murphy, III". The signature is stylized and somewhat cursive.

John Murphy, III  
AAM President & CEO